Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world senaparib first-line maintenance in advanced ovarian, fallopian tube, or primary peritoneal cancer
ChiCTR2600120564Phase 4Not yet recruiting
- Sponsor
- Peking Union Medical College Hospital
- Start
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of senaparib in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC), sponsored by Peking Union Medical College Hospital. Primary endpoint: Progression-free survival. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
senaparib
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on ChiCTR2600120564.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600120564.